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Abstract
Objective—Some individuals are diagnosed with colorectal cancer (CRC) despite recent 
colonoscopy. We examined individuals under colonoscopic surveillance for colonic adenomas to 
assess possible reasons for diagnosing cancer after a recent colonoscopy with complete removal of 
any identified polyps.
Design—Primary data were pooled from eight large (>800 patients) North American studies in 
which participants with adenoma(s) had a baseline colonoscopy (with intent to remove all 
visualised lesions) and were followed with subsequent colonoscopy. We used an algorithm based 
on the time from previous colonoscopy and the presence, size and histology of adenomas detected 
at prior exam to assign interval cancers as likely being new, missed, incompletely resected (while 
previously an adenoma) or due to failed biopsy detection.
Results—9167 participants (mean age 62) were included in the analyses, with a median follow-
up of 47.2 months. Invasive cancer was diagnosed in 58 patients (0.6%) during follow-up (1.71 
per 1000 person-years follow-up). Most cancers (78%) were early stage (I or II); however, 9 
(16%) resulted in death from CRC. We classified 30 cancers (52%) as probable missed lesions, 11 
(19%) as possibly related to incomplete resection of an earlier, non-invasive lesion and 14 (24%) 
as probable new lesions. The cancer diagnosis may have been delayed in three cases (5%) because 
of failed biopsy detection.
Conclusions—Despite recent colonoscopy with intent to remove all neoplasia, CRC will 
occasionally be diagnosed. These cancers primarily seem to represent lesions that were missed or 
incompletely removed at the prior colonoscopy and might be avoided by increased emphasis on 
identifying and completely removing all neoplastic lesions at colonoscopy.
Introduction
Colorectal cancer (CRC) is the second most common cause of cancer death in the USA and 
its prevention and early detection are a significant public health concern.1 The United States 
Preventive Services Task Force and the American Cancer Society in collaboration with the 
US Multi-Society Task Force, among other organisations, recommend that adults be 
screened for CRC.23 These recommendations are based on high quality evidence that 
screening can reduce CRC mortality45 and incidence6 and recent studies show that 
nationally CRC incidence and mortality are declining.7
Colonoscopy appears to be a highly effective modality for screening and affords the 
opportunity to view the entire colorectal mucosa and simultaneously remove premalignant 
adenomas before they become invasive cancers. While no large randomised controlled trials 
of screening colonoscopy have been reported, recent observational studies suggest that 
colonoscopy in the prior 10 years may reduce CRC incidence and mortality by over 60%.89
Despite evidence of colonoscopy's effectiveness, some individuals are diagnosed with CRC 
relatively soon after a colonoscopy that deemed the colon to be free of neoplasia. These 
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‘interval’ cancers (ie, those that appear to arise between serial colonoscopies) have been 
observed in studies examining large administrative data sets1011 and national screening 
programmes12 as well as in smaller clinical studies.13–16 However, relatively few reports1317 
have explored the possible explanations for these interval cancers. Investigators from the 
Polyp Prevention Trial (PPT) identified 13 CRCs that occurred during the follow-up phase 
of that study. Using an algorithm, they estimated that roughly a half were potentially 
avoidable, being likely missed or the result of a prior incompletely resected polyp.13 At a 
single Veterans Affairs (VA) centre, records of 45 patients with interval CRCs were 
examined and 12 (27%) developed cancer in the same segment of the colon from which a 
prior polyp had been removed.17 Incomplete resection of a prior lesion was felt to be the 
explanation in those cases. In a clinical series of cases from 20 Indiana hospitals, 47 CRCs 
were identified within 3 years of a colonoscopy not detecting cancer.16 After review, 27 
cases (57%) were felt to be missed cancers.
We used a pooled dataset from eight large prospective studies to assess both the frequency 




The pooled analyses used patient-level data from eight North American studies18–26 of 
patients with sporadic colorectal neoplasia. The details regarding the patients enrolled in the 
individual studies have been reported previously27 and are summarised in table 1. We 
included studies that met the following criteria: (1) enrolled ≥800 participants; (2) protocol 
required complete baseline colonoscopy with removal of all visualised lesions, of which at 
least one was an adenoma; (3) specified the schedule of follow-up colonoscopies; and (4) 
obtained data regarding the number, size and histopathology of neoplasms detected in 
follow-up examinations. All of the studies excluded subjects known to be affected by Lynch 
Syndrome or familial adenomatous polyposis. To our knowledge, we included all studies 
meeting these criteria that had reported findings by June 2005. Of the 10 021 men and 
women who were enrolled in the individual studies, we excluded those who had a CRC 
present at study entry (n=27) and those who had no follow-up colonoscopy performed after 
their first 6 months of study (n=827) since these likely were not under typical 
postpolypectomy surveillance (ie, did not undergo follow-up colonoscopy exams during the 
surveillance period that started 6 months after the baseline exam). Thus, our pooled analyses 
included data for 9167 (91.5%) of all enrolled patients.
Study endpoints
We identified all participants in the pooled dataset who were diagnosed with invasive cancer 
after the initial complete colonoscopy and during the main observation period of each study 
(typically 3–4 years). Most of the descriptive information presented on the cancer cases was 
derived directly from the pooled data set, including patient demographics, cancer size and 
location, as well as information on patient outcome (eg, mortality/cause of death). Staff at 
each study centre also reviewed the endoscopy and pathology reports to confirm the 
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presence of cancer and to abstract data on other clinical details including presenting 
symptoms (if any), cancer stage and grade where available.
Algorithm to adjudicate cancer cause
Building on prior work by others,13 we developed an algorithm to assign a presumptive 
explanation for the interval cancer in each case (figure 1 and table 2). Using information 
regarding the timing and findings on the colonoscopy prior to the one detecting cancer 
(often but not necessarily the baseline exam), each case was assigned to one of four 
categories: ‘new cancer,’ ‘missed lesion,’ ‘incomplete adenoma resection’ and ‘failed biopsy 
detection.’ To be adjudicated as a ‘new cancer’, three or more years must have passed 
between the prior colonoscopy and the exam diagnosing cancer, and there must have been 
no significant adenoma detected in the same segment of the colorectum on the prior exam, 
as described below. Similarly, cancers were assigned as ‘missed lesions’ if they were found 
within 3 years of the prior colonoscopy and there was no evidence of a significant adenoma 
in the same segment at that exam. To ascribe a case as ‘incomplete adenoma resection’ there 
had to be a ‘significant’ adenoma resected from the same segment of the colon during the 
prior colonoscopy. Given that adenomatous polyps increase in size over time, the definition 
of what constituted a significant adenoma varied based upon on the time since last 
colonoscopy. Specifically, if three or more years had passed since the last colonoscopy, then 
an adenoma ≥5 mm in size, or with villous histology or with high grade dysplasia was 
considered significant. If fewer than 3 years had passed, then an adenoma ≥1 cm in size, or 
with villous histology or with high grade dysplasia was considered significant.
The label ‘failed biopsy detection’ was used to categorise those cases occurring within 1 
year of the previous exam and in the same segment of the bowel as an adenoma and in 
which the endoscopist was suspicious that cancer may have been present. In these situations, 
repeated exams might be required to make what is ultimately a delayed diagnosis.13 For this 
category, we assumed the interval between the colonoscopy diagnosing cancer and the prior 
colonoscopy would be short (1 year or less) since endoscopists with heightened clinical 
suspicion for cancer would unlikely recommend follow-up at longer intervals.
To distinguish between incomplete resection (endoscopist indicates no real concern for 
residual neoplasia) and failed biopsy detection (endoscopist not sure that the lesion was 
effectively sampled and/or removed), we performed chart review of available data (eg, 
colonoscopy reports) of all cases that occurred less than 1 year after a colonoscopy in which 
an adenoma was identified in the same segment of the bowel as the subsequent cancer. 
Previously published criteria13 were used to guide reviewers (DJR and PL) of those cases. 
To further clarify how clinical data were used to adjudicate cases, examples are provided in 
the supplementary material (see online supplementary table S1).
Two reviewers (DJR, DAL) guided by the algorithm independently ascribed a presumptive 
reason for each interval cancer. If their assessments disagreed, then a third reviewer (SJW) 
adjudicated the case. At that point, if two of the three reviewers agreed on a classification, 
that determination was recorded. In one of the 58 cases the assessments of the three 
reviewers all differed, and a single investigator (DJR) reviewed the primary clinical data for 
the case, without using the algorithm, and assigned a likely explanation.
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We used summary statistics to describe the baseline characteristics of the pooled study 
cohort and t tests and contingency tables to compare the characteristics of patients who 
developed interval cancer with those who did not. Follow-up time (for incidence 
calculations) includes time under observation from qualifying colonoscopy until the 
diagnosis of CRC or through last study colonoscopy for those not detected with CRC. 
Contingency tables were also used when determining whether the adjudicated explanation 
for interval cancer was associated with symptomatic presentation or the location of the 
cancer. Given reports that colonoscopy may be less effective in preventing right-sided 
cancers,2829 we examined the data according to whether or not the interval cancer was 
located proximal to the splenic flexure (ie, right sided). We used κ statistic to assess inter-
rater agreement when using the algorithm.
Results
The 9167 studied patients were mostly men (71.2%) and Caucasian (89.1%), and their mean 
age was 62.0 years. The median clinical follow-up for the entire patient group was 47.2 
months (range of medians among studies 36.9–59.0 months) and the majority underwent at 
least one colonoscopy during that period, ranging among studies from 81% in the National 
Polyp Study (NPS) to 97% in the VA study.27
A total of 58 patients (0.63%) were diagnosed with invasive CRC following a colonoscopy 
that had been deemed clear of neoplasia for an incidence rate of interval cancers of 1.71 per 
1000 person-years of follow-up. In 46 cases (79%), the indication for the colonoscopy that 
detected the cancer was routine surveillance. In nine cases, the indication was symptoms 
suggestive of CRC, and the other three were performed to follow-up an abnormal 
colonoscopic finding or at patient request. Patients found with cancer were older (mean 
age=67.4±6.9 years) than those without cancer (mean age=61.9±9.5 years; p=0.0003) and 
were more likely to be men (86.2% of those with cancer vs 71.1% of those without; 
p<0.0001).
Interval cancers were detected in each of the eight studies (table 3) and were distributed 
throughout all sections of the large bowel: 29 (50%) were on the right side of the colon and 
most (78%) were Stage I or II (see online supplementary material table S2). However, nine 
of the patients with cancer (15%) subsequently died of CRC during a median follow-up of 
4.7 years in these cases. The incidence of interval cancer varied across studies ranging from 
a low of 1.14 cancers/1000 person-years of follow-up (NPS) to a high of 2.24 cancers per 
1000 person-years of follow-up (Calcium Polyp Prevention Study). In four of the eight 
studies at least one subject died of CRC.
The clinical reviewers were generally consistent in ascribing potential explanations to the 
interval cancers. Of the 58 cases with cancer, four were excluded from the κ statistic 
calculation because chart review was required by protocol (three cases), or all reviewers 
agreed that chart review was necessary (one case). For the other 54 cases, there was 78% 
agreement between the primary and secondary reviewers (κ =0.64). The putative reason for 
the interval cancers was missed lesions for 30 cases (52%), incomplete adenoma resection 
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for 11 cases (19.0%) and new cancer for 14 (24%); the remaining three cases (5%) were 
categorised as failed biopsy detection. Of the nine patients who died of CRC, seven were 
ascribed to missed lesions and two to new lesions.
Interval cancers on the right side of the colon were statistically significantly more likely to 
be classified as missed (19/29) than those on the left side (11/29) (p=0.04, table 4). In 16% 
of the cases, clinical symptoms were the indication for the exam that detected cancer (table 
5). Interval cancers detected on these exams were more likely to be adjudicated as missed 
lesions (8/9) than those detected at routine surveillance (20/46) (p=0.01).
Discussion
Using pooled data on 9167 adenoma patients from eight large North American studies, we 
identified 58 individuals diagnosed with CRC in a short interval (median follow-up 4 years) 
after a complete colonoscopy and polypectomy that was intended to have left the colon free 
of neoplasia. Upon review, nearly three-quarters of these cancers were judged to be the 
possible result of a missed lesion, incomplete adenoma resection or failed biopsy detection, 
and thus were potentially preventable or detectable at an earlier stage.
Several studies 13–1630–38 have reported on incident cancers in patients under colonoscopic 
surveillance, including four of the trials included in this report.13–1538 Overall, there is some 
heterogeneity in the incidence rates reported across these studies and some have proposed 
explanations35 for these observed differences. Study specific factors such as the composition 
of the population (ie, whether individuals with large polyps were excluded) and whether or 
not participant follow-up ended with surveillance endoscopy are likely important. For 
example, studies that exclude patients with very large polyps1531 tend to report lower 
incidence rates of cancer. The frequency of colonoscopic examination may also be an 
important factor since more frequent colonoscopy affords greater opportunity to detect small 
asymptomatic cancers. Of the eight studies included in our analyses, the one with the highest 
observed cancer incidence20 also had the largest percentage of participants with one or more 
colonoscopies during the study period. Conversely, the study with the lowest observed 
cancer incidence25 had the lowest percentage of participants with one or more colonoscopies 
during the study period.
To our knowledge, only one prior study has categorised early interval cancers as to the 
reasons for their occurrence.13 The PPT investigators examined 13 interval cancers, all of 
whom are also included in our current report, and estimated that seven were potentially 
‘avoidable’ because they were categorised as incomplete removals or missed lesions. We 
employed similar methodology, but we required a slightly longer dwell time for a lesion to 
be adjudicated as a new cancer (36 vs 30 months) and did not consider the stage of the 
detected cancer in our determination. Also, unlike the PPT, we judged most cases based 
solely upon colonoscopy data (eg, polyp size, location, histology) recorded in the pooled 
data set—not the actual endoscopy and pathology reports. Only for potential cases of failed 
biopsy detection was the primary data reviewed to distinguish these cases from cases of 
incomplete resection. Overall, compared with the PPT report, we ascribed a higher 
percentage of interval cancers as missed lesions (52% vs 23%) and a lower percentage as 
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‘failed biopsy detection’ cases (5% vs 23%). We did not allow ‘failed biopsy detection’ as 
an explanation if more than 1 year had transpired between colonoscopies (based on our 
assumption that a shorter interval would have been recommended if there were concerns 
about missed cancer). Two of the three cases adjudicated as ‘failed biopsy detection’ in the 
PPT report occurred in cases where more than 1 year transpired between colonoscopies, and 
thus we assigned a different putative explanation for similar cases. Had we assumed, like the 
PPT investigators, that more advanced stage lesions were likely missed, we would have 
further increased the number of our cancers adjudicated as ‘missed’. These differences attest 
to the difficulty of ascertaining the reasons for the occurrence of interval cancers.
While it is impossible to know the exact frequency of important missed lesions during 
colonoscopy, they unarguably occur. In one study, using a tandem colonoscopy design, 
adenoma miss rates of 6% for lesions ≥1 cm were observed,39 and a meta-analysis of 
tandem colonoscopy studies estimated that 2% of large adenomas are missed.40 In studies of 
CT colonography that used segmental unblinding, optical colonoscopy missed 11%–17% of 
lesions ≥1 cm.41–43 More than a half of the interval cancers in this pooled analysis were 
adjudicated as likely missed lesions. Also, in our analysis, symptomatic cancers were more 
likely to be classified as missed on the prior examination.
Inadequate bowel preparation for colonoscopy is one plausible explanation for missing 
significant neoplasia at the time of colonoscopy. One study, using data from the Clinical 
Outcomes Research Initiative database, examined the association of bowel preparation 
quality and adenoma detection rates in 93 004 colonoscopies and found that adequate 
preparation was associated with a higher rate of colorectal lesion detection (OR=1.21 for 
detection of one or more lesions; 95% CI 1.16 to 1.25).44 In the NPS, the baseline 
colonoscopy was deemed inadequate in 13% of the cases and therefore was repeated. This 
factor may have contributed to the lower rates of subsequent cancer incidence relative to 
other studies, although none of the studies in our pooled analysis included subjects whose 
colonoscopy preparation was known to be inadequate. After the first year of follow-up, 
cancer incidence rates observed in the other studies included in our pooled analysis were 
similar to those observed in the NPS, supporting the importance of the quality of the 
baseline clearing colonoscopy.45
The contribution of flat and depressed colorectal polyps to the occurrence of interval 
cancers, likely through the mechanism of missed lesions, has been a focus of intense interest 
and debate.46 While these lesions have long been described in the Japanese literature, there 
has been controversy about the frequency of their occurrence in Western populations. One 
US study analysing a veteran population suggested that non-polypoid colorectal neoplasms 
accounted for nearly 10% of the adenomas removed and that these lesions were more likely 
to contain in situ or submucosal carcinoma than their polypoid counterparts (OR, 11.1; 95% 
CI 4.98 to 24.8).47 However, a study using NPS data48 concluded that such lesions have 
long been recognised, but often termed ‘sessile’ rather than flat. When all baseline ‘sessile’ 
polyps in the NPS were recategorised based upon review of pathology specimens, 27% 
would have met formal definition as a ‘flat’ adenoma. Patients with these flat lesions were 
not at a significantly higher risk for advanced adenomas at baseline or at the 3-year follow-
up exam. We cannot specifically comment on the role of flat polyps, if any, in the current 
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pooled study as polyp shape was not a variable abstracted into the pooling study data 
repository.
Another potential explanation for early interval cancer is incomplete resection of prior 
adenomas, and we judged that 11 (19%) of our interval cancers were in this category. Our 
findings are generally consistent with a retrospective study from a single VA centre in which 
12 of 45 interval cancers (27%) occurred in the same segment where a polyp had been found 
on the prior exam.17 Incomplete resection is likely to be particularly relevant to large 
lesions. Our research group has previously reported that the risk of advanced neoplasia was 
higher in patients with baseline adenomas ≥20 mm, highlighting the importance of this 
factor.27
Current guidelines suggest short term follow-up (eg, 3–6 months) for sessile lesions 
removed piecemeal to assure complete resection.49 The importance of incomplete resection 
is increasingly being recognised. In one recent study, 345 adenomatous polyps were 
removed and margins were biopsied to assess adequacy of resection; 10% showed evidence 
of residual adenoma.50 One reason for the relatively low cancer incidence observed in the 
NPS could be that the study excluded patients with large (>3 cm) polyps, which are the ones 
most likely to be incompletely resected. The parent clinical trials composing the pooled 
cohort required that each participant's colon be believed free of residual neoplasia at study 
entry. Those individuals recently undergoing resection of large sessile polyps where there 
was concern of residual neoplasia were not included. Our observed rate of interval neoplasia 
would likely be higher had such individuals been enrolled into the studies.
A limitation of our study is that the adjudication of the reasons for the interval cancers relied 
on our algorithm, which necessarily made assumptions about the course of colorectal 
carcinogenesis (eg, the dwell time from adenoma to cancer). Thus, it is impossible to know 
the actual natural history of the interval cancers in our study, and we likely have 
misclassified some cases. For example, we adjudicated many cancers as due to missed 
lesions only because they were found within 3 years of the prior colonoscopy at which no 
adenoma was identified in the same segment; however, a new cancer could have developed 
from visually-normal mucosa during that time. Adenoma dwell time (ie, from adenoma 
incidence to cancer) has recently been estimated in three microsimulation models51 and our 
time window of 3 years is lower than those estimates which range from 7.6 to 24.2 years. To 
the extent that we have underestimated adenoma dwell time in developing our algorithm, we 
have reduced the number of cases explained by ‘missed’ and increased those explained as 
‘new’. Similarly, we cannot exclude that some cancers adjudicated as incomplete resection 
represent new cancers growing in the area where a prior adenoma was removed. Also, to be 
consistent with terminology used in prior studies we based our algorithm on one previously 
published.13 Distinguishing cases of ‘failed biopsy detection’ from ‘incomplete resection’ is 
difficult by record review, since the determination relies partly on the endoscopist's 
suspicion of residual cancer being present at the site of a prior biopsy. One could argue that 
a truly ‘failed biopsy’ would detect only benign tissue, but for consistency with previous 
research, we retained the prior definition. Although the use of an algorithm to assign 
possible explanation for the observed cancers has limitations, the algorithm was developed 
Robertson et al. Page 8













prior to review, and adjudication of the cases was done independently with good agreement 
between reviewers.
Also it is important to note that we have not tested tumour tissue for either microsatellite 
instability (MSI) or CpG island methylator phenotype (CIMP) and cannot determine 
whether these mechanistic pathways are playing a role in the cases described here. In 
patients with hereditary non-polyposis CRC, cancers with loss of mismatch repair gene 
function have accelerated tumour growth.52 It is possible that this extends to sporadic MSI-
high cancer. One study has reported that early interval cancers are three times more likely to 
have evidence of MSI-high MSI as compared with non-interval cancers.53 There is also 
evidence that interval cancers are more likely to demonstrate CIMP than non-interval 
cancers.54
A final limitation of our work relates to the composition of the pooled cohort itself. All 
participants were enrolled in clinical studies and the colonoscopy exams may have been 
performed differently than those in general practice. In fact, our absolute rate of observed 
cancer (0.6%) after colonoscopy is significantly less than an estimate based on Medicare 
administrative data (7.2%).55 Also, the trials enrolling these participants were performed 
many years ago prior to improvements in endoscope technology (eg, high definition 
endoscopes) and emphasis on issues of colonoscopy quality (eg, adenoma detection rate, 
withdrawal time). Finally, our cohort was not equally balanced with respect to gender (71% 
male). There is a prior study that demonstrated missed lesions, particularly on the right side 
of the colon, occur more frequently in women. Overall, we found that male gender was 
associated with an increased risk for postcolonoscopy CRC. That study largely included 
individuals without prior colonoscopy, and so their findings may differ from ours in part 
because of this.
In conclusion, we estimate that approximately 6/1000 individuals were diagnosed with 
interval cancer within an average of 4 years following a complete colonoscopy with removal 
of ‘all’ polyps. Our review suggests that many of the interval cancers might have been found 
earlier or perhaps excised while still an adenoma at the prior colonoscopy exam. The large 
pooled patient population drawn from studies with prospectively collected data and high 
rates of complete colonoscopy follow-up all enhance the value of the results reported here. 
These results emphasise the importance of performing colonoscopic examinations with 
meticulous attention to the identification and complete removal of all suspected neoplasms.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance of this study
What is already known on this subject?
• Colonoscopy is highly sensitive for the detection of polyps and cancer.
• However, colorectal cancer has been detected in relatively short intervals after 
colonoscopy that deemed the colon free of cancer.
• The likely explanation for these postcolonoscopy cancers is not known.
What are the new findings?
• Approximately 6/1000 individuals were diagnosed with interval cancer within 
an average of 4 years following a complete colonoscopy.
• Missed lesions and incompletely resected lesions appeared to account for about 
70% of postcolonoscopy cancers in our series.
How might it impact on clinical practice in the foreseeable future?
• Meticulous colonoscopy technique including mucosal inspection and complete 
lesion resection are likely the most important factors in reducing the frequency 
of early interval cancer.
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Algorithm used to determine likely cause for early interval cancers and distribution of 
cancers based upon algorithm review for most likely causes.
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Table 2
Summary of adjudication strategy based on interval since last colonoscopy and the 
presence of a significant lesion in the same section of the colon on prior colonoscopy
Time interval since last colonoscopy
Significant lesion found in 
same segment on prior 
colonoscopy
≤1 year* >1 year to <3 years† ≥3 years‡
Yes Incomplete adenoma resection Or Failed biopsy detection Incomplete adenoma Resection Incomplete adenoma Resection
No Missed lesion Missed lesion New cancer
*
Cases required hand review to distinguish.
†
Significant lesion defined as adenoma with advanced histology or ≥1 cm.
‡
Significant lesion defined as adenoma with advanced histology or ≥5 mm.
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Table 4
Association of proposed explanation for interval cancer and location of interval cancer
Proposed explanation for interval cancer Median time from baseline colonoscopy (years) Location of interval cancer
Right (N=29)* N (%) Left (N=29) N (%)
Missed (N=30) 2.3 19 (65.5) 11 (37.9)
Incomplete removal (N=11) 2.9 4 (13.8) 7 (24.1)
New (N=14) 3.5 4 (13.8) 10 (34.5)
Failed biopsy detection (N=3) 2.0 2 (6.9) 1 (1.2)
*
Right colon defined as proximal to the splenic flexure.
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